Rhabdomyolysis during therapy with daptomycin
Rhabdomyolysis during therapy with daptomycin
复制标题
DOI：
10.1086/504379
复制
发表时间：
2006-06-15
影响因子：
11.8
通讯作者：
Murphy, Brian S.
中科院分区：
文献类型：
--
作者：
Papadopoulos, Stella;Ball, Amanda M.;Murphy, Brian S.
达托霉素的使用与肌酸磷酸激酶水平升高有关，在 III 期临床试验中报告的发生率为 2.8%。已发表的病例报告记录了接受达托霉素治疗的患者存在肌病；然而，迄今为止还没有动物或人类横纹肌溶解症的报道。我们描述了达托霉素治疗期间发生横纹肌溶解的病例。
The use of daptomycin has been associated with an elevation in creatine phosphokinase level, with a reported incidence of 2.8% in phase III clinical trials. Published case reports have documented the presence of myopathy in patients who received daptomycin; however, there have been no previously reported cases of rhabdomyolysis in animals or humans to date. We describe a case of rhabdomyolysis during therapy with daptomycin.